<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="609">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05153226</url>
  </required_header>
  <id_info>
    <org_study_id>DKMS-21-01</org_study_id>
    <nct_id>NCT05153226</nct_id>
  </id_info>
  <brief_title>GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG</brief_title>
  <acronym>GRAPPA</acronym>
  <official_title>Graft vs Host Disease Prophylaxis in Unrelated Donor Transplantation: a Randomized Clinical Trial Comparing PTCY vs ATG (GRAPPA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DKMS gemeinnützige GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DKMS gemeinnützige GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-transplantation cyclophosphamide (PTCY) has become increasingly popular in the&#xD;
      haploidentical HCT setting because it overcomes the HLA-mismatch barrier and levels GVHD&#xD;
      risk. This advantage may also prove useful in the context of unrelated donor (UD)&#xD;
      transplantation. GVHD prophylaxis for matched unrelated donor hematopoietic cell&#xD;
      transplantation (alloHCT) in Europe is mainly conducted with ATG. Still, the burden of acute&#xD;
      and chronic GVHD and especially of relapse remains high with both approaches for GVHD&#xD;
      prevention.&#xD;
&#xD;
      PTCY has not been tested against the current standard ATG for GvHD prophylaxis in large&#xD;
      randomized trials. The goal of this trial is to compare the outcomes of PTCY and ATG for&#xD;
      patients receiving unrelated donor PBSCT. PTCY-based prophylaxis promises to have beneficial&#xD;
      net effects on immune reconstitution, GVHD and disease control, and thus might impact on&#xD;
      patient survival.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">August 2026</completion_date>
  <primary_completion_date type="Anticipated">August 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival from HCT</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Relapse- and Immunosuppression-free Survival (RIFS)</measure>
    <time_frame>1 year after HCT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GVHD-and relapse-free survival (GRFS)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of non-relapse mortality</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidences of acute and chronic GVHD</measure>
    <time_frame>180 days and 2 years after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">540</enrollment>
  <condition>Graft Vs Host Disease</condition>
  <condition>Peripheral Blood Stem Cell Transplantation</condition>
  <condition>AML</condition>
  <condition>MDS</condition>
  <condition>MDS/MPN</condition>
  <condition>CMML</condition>
  <arm_group>
    <arm_group_label>Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclophosphamide 50 mg/kg (AIBW) i.v. d+3, d+4 post transplant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ATG Grafalon 10 mg/kg i.v. d-3, d-2, d-1 pre-transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>50 mg/kg (AIBW) i.v. d+3, d+4 post transplant</description>
    <arm_group_label>Cyclophosphamide</arm_group_label>
    <other_name>all brands</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ATG</intervention_name>
    <description>10 mg/kg i.v. d-3, d-2, d-1 pre-transplant</description>
    <arm_group_label>ATG</arm_group_label>
    <other_name>ATG Grafalon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written Informed Consent and able to understand the nature of the trial and the&#xD;
             trial related procedures and to comply with them.&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  One of the following eligible diagnoses: AML in CR1 with intermediate or adverse risk&#xD;
             genetic abnormalities (according to the ELN 2017 guidelines), or undefined risk. AML&#xD;
             of any ELN risk category after hematological or molecular relapse, or with primary&#xD;
             refractory disease. AML arising from myelodysplastic syndrome (MDS) or a&#xD;
             myeloproliferative neoplasia, except if favourable genetic abnormalities (according to&#xD;
             ELN 2017 guidelines) are present. Therapy-related myeloid neoplasia (t-MN), except if&#xD;
             favourable genetic abnormalities (according to ELN 2017 guidelines) are present. MDS&#xD;
             with intermediate risk, high risk or very high risk disease (according to the IPSS-R&#xD;
             Score) regardless of treatment status. MDS/MPN and CMML-1/CMML-2 regardless of&#xD;
             treatment status.&#xD;
&#xD;
          -  The left ventricular ejection fraction (LVEF) was assessed ≥40% at last&#xD;
             echocardiography.&#xD;
&#xD;
          -  Transplantation with Peripheral Blood Stem Cells (PBSC) scheduled to be performed 4 to&#xD;
             14 days after date of randomization.&#xD;
&#xD;
          -  The scheduled donor is unrelated to the patient, and matched or partially matched&#xD;
             (with not more than one allele or antigen mismatch) at HLA-A, -B, -C, or -DRB1.&#xD;
&#xD;
          -  Absence of pregnancy confirmed by highly sensitive pregnancy test for WOCBP. Test must&#xD;
             not date back more than 3 days prior to randomization, or more than 3 days prior to&#xD;
             start of conditioning, if it started before randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anamnestic intravenous or subcutaneous exposure to rabbit immunoglobin-preparations&#xD;
             (e.g. Grafalon or Thymoglobulin)&#xD;
&#xD;
          -  Known hypersensitivity to ATG-Grafalon or its excipients.&#xD;
&#xD;
          -  Known hypersensitivity to cyclophosphamide, its metabolites or excipients.&#xD;
&#xD;
          -  Prior allogeneic hematopoietic transplantation.&#xD;
&#xD;
          -  Patients who receive supplementary continuous oxygen at the time of randomization.&#xD;
&#xD;
          -  Symptomatic heart failure (NYHA ≥2) at the time of randomization.&#xD;
&#xD;
          -  Uncontrolled viral, bacterial or fungal infection with progression or no clinical&#xD;
             improvement at the time of randomization.&#xD;
&#xD;
          -  Symptomatic cystitis or known obstruction of urine flow at the time of randomization.&#xD;
&#xD;
          -  Breast-feeding women.&#xD;
&#xD;
          -  WOCBP and fertile male patients unable or unwilling to follow highly effective&#xD;
             contraception methods from enrollment to minimum six months after the last dose of the&#xD;
             IMP.&#xD;
&#xD;
          -  Simultaneous participation in another interventional clinical trial with an&#xD;
             investigational medicinal product.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Schetelig, Prof Dr med</last_name>
    <role>Study Chair</role>
    <affiliation>Universitätsklinikum Dresden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Trost, MSc</last_name>
    <phone>+49 351 210 798</phone>
    <phone_ext>28</phone_ext>
    <email>grappa@dkms.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinikum Chemnitz gGmbH</name>
      <address>
        <city>Chemnitz</city>
        <zip>09113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <investigator>
      <last_name>Mathias Hänel, PD Dr med habil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <investigator>
      <last_name>Johannes Schetelig, Prof Dr med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60595</zip>
        <country>Germany</country>
      </address>
    </facility>
    <investigator>
      <last_name>Gesine Bug, Dr med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale)</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <investigator>
      <last_name>Lutz Peter Müller, PD Dr med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <investigator>
      <last_name>Lorenz Thurner, PD Dr med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <investigator>
      <last_name>Inken Hilgendorf, PD Dr med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <investigator>
      <last_name>Eva Maria Wagner-Drouet, Dr med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <investigator>
      <last_name>Stefan Klein, PD Dr med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <investigator>
      <last_name>Matthias Stelljes, Prof Dr med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
    <investigator>
      <last_name>Christian Junghanß, Prof Dr med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <investigator>
      <last_name>Wolfgang Bethge, Prof Dr med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 26, 2021</study_first_submitted>
  <study_first_submitted_qc>December 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2021</study_first_posted>
  <last_update_submitted>December 9, 2021</last_update_submitted>
  <last_update_submitted_qc>December 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Graft vs Host Disease</keyword>
  <keyword>Peripheral Blood Stem Cell Transplantation</keyword>
  <keyword>Cyclophsophamide</keyword>
  <keyword>Anti-thymocyte globulin (rabbit)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

